The veterinary monoclonal antibodies market is growing steadily due to rising rates of chronic diseases in animals and increasing pet ownership.
The veterinary monoclonal antibodies industry is poised for strong expansion as companion-animal care becomes more sophisticated and pet owners treat their pets with advanced biologic therapies. Monoclonal antibodies (mAbs) in veterinary use target specific disease pathways in animals – much like their human-medicine counterparts – offering new treatment options for chronic and acute conditions.
According to research, the global veterinary monoclonal antibodies industry was estimated at around USD 1.52 billion in 2024, and is projected to reach roughly USD 3.06 billion by 2030, growing at a CAGR of about 12.4% from 2025 to 2030
In short, the industry is scaling up — both in absolute size and in growth momentum.
Download PDF Brochure
Industry Share & Segment Highlights
Product & Device Segments
Within the biologic therapy category for animals, monoclonal antibodies are used across different applications: dermatology (skin diseases), pain/osteoarthritis in pets, oncology, and increasingly infectious-disease treatment. For example, the dermatology segment led revenue share in 2024.
The canine segment is dominant (dogs are the largest animal type) in this industry.
Application & End-User Segments
By therapy area, dermatology (e.g., atopic dermatitis in dogs) holds the largest share; oncology and infectious diseases are rising fast. By end-user, veterinary hospitals and clinics dominate demand since advanced therapies are typically administered in these settings.
Regional & Share Breakdown
North America holds the largest share in this industry due to strong pet-ownership rates, higher veterinary healthcare spend, and established biologic-therapy infrastructure. For instance, about 43-45% of revenue in 2024 came from North America.
Asia-Pacific is identified as the fastest growing region in many reports.
Key Drivers & Trends Shaping the Industry
Rising Pet Ownership & Pet Health Spend
The number of companion animals worldwide continues to grow, and pet owners increasingly view animals as family members — driving willingness to spend on more advanced treatments. The rise in chronic diseases such as atopic dermatitis, osteoarthritis, cancers and immune disorders in dogs and cats is pushing demand for novel therapies like monoclonal antibodies.
Technological Advancement & Biologic Innovation
Advances in biologic engineering, targeted immunotherapies, veterinary-specific mAbs, subcutaneous formulations, and better delivery systems are key trends in the veterinary monoclonal antibodies industry. For example, subcutaneous administration is becoming popular due to ease of use and compliance in animals.
Expanded Therapy Areas
While initially these therapies focused on dermatological conditions and pain/osteoarthritis (especially in dogs), pipeline development is increasing into infectious diseases, oncology and other immune-mediated conditions in animals.
Growing Awareness & Premium Veterinary Care
Pet owners in many regions now expect higher standards of veterinary care, including biologic therapies. Also, veterinary professionals are more educated about the benefits of mAbs.
This premiumization supports the industry’s upward trajectory.
Industry Challenges & Restraints
Despite the strong growth outlook, there are a few headwinds:
* High cost of biologic therapies: Monoclonal antibodies remain expensive compared to more conventional veterinary treatments, limiting adoption in lower-spend regions.
* Regulatory and development hurdles: The veterinary biologics regulatory frameworks (which vary by region) and long development pipelines for novel mAbs can slow the industry’s speed.
* Infrastructure & veterinary expertise: In some emerging regions, veterinary hospitals/clinics may lack the infrastructure or specialist expertise to adopt advanced biologics.
* Reimbursement and pet-insurance limitations: In many markets, pet insurance is limited or biologic therapies may not be covered, reducing uptake among cost-sensitive owners.
Competitive Landscape – Top Companies & Industry Share
The veterinary monoclonal antibodies industry is actively contested by leading animal-health and biologics companies. Some of the prominent players include:
* Zoetis Services LLC (US) – A major player in companion-animal health and biologic treatments.
* Elanco Animal Health (US) – Actively involved in veterinary mAb development and commercialization.
* Merck & Co., Inc. (US) Animal Health division – With biologic and veterinary health focus, including monoclonal antibodies.
* Virbac (France) – Developing veterinary biologics including mAbs, through licensing and partnerships.
These companies, among others, are driving innovation, expanding product portfolios and scaling manufacturing to capture share in this growing industry.
Request Sample Report
Future Outlook & What to Watch
* Strong growth ahead: With projected CAGRs ranging from ~12 % to ~19 %, the veterinary monoclonal antibodies industry is positioned for considerable growth in the next 5-10 years.
* Home-care/Outpatient adoption: As veterinary care evolves, there will be more demand for injectable biologics that can be administered outside high-cost hospital settings (e.g., clinics, specialty vet centres).
* Pipeline expansion: New mAbs will target previously underserved indications in animals — oncology, infectious diseases, immune-mediated disorders — broadening the therapeutic base.
* Manufacturing & cost-efficiency: Advances in biologics manufacturing, including single-use bioreactors, outsourcing (CDMOs) and optimized supply chains will help scale cost and reach.
* Emerging markets: While North America remains dominant, emerging geographies (Asia-Pacific, Latin America) offer significant upside if regulatory, cost and infrastructure barriers are addressed.
* Pet insurance & reimbursement dynamics: Growth will be supported if pet-insurance penetration increases and biologic treatments become more widely reimbursed/accepted by owners.
Conclusion
The veterinary monoclonal antibodies industry stands at a pivotal stage of transformation. With increasing size, expanding therapeutic applications, and rapid innovation, this domain is emerging as a major pillar of advanced veterinary care.
The industry’s growth is supported by rising pet populations, chronic disease prevalence in animals, evolving owner expectations and biologic technology breakthroughs.
For companies, investors and veterinary service providers looking ahead, focusing on industry size, growth, share dynamics, top companies, trends, and technology advances will be key to positioning for success.
In short: the veterinary monoclonal antibodies industry is not only growing in size and share — it is evolving into a more connected, accessible and biologics-driven ecosystem for companion animals.
News From
MarketsandMarkets™
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w …
This email address is being protected from spambots. You need JavaScript enabled to view it.
